{"schema_version":"secwatch.filing_event.v1","accession":"0001664710-25-000071","form_type":"8-K","ticker":"KROS","cik":"0001664710","company_name":"Keros Therapeutics, Inc.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.591641+00:00","generated_at":"2026-05-17T19:35:56.462374+00:00","sec_items":["5.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Keros discontinues cibotercept development, prioritizes KER-065; CEO becomes President, COO departs","bullets":["Discontinuing all internal development of cibotercept (KER-012) after PAH trial termination.","Exclusively prioritizing KER-065 for Duchenne muscular dystrophy; Phase 2 expected Q1 2026.","CEO Jasbir Seehra adds President role effective Aug 18, 2025; steps down as Board Chair.","Jean-Jacques Bienaimé appointed Chair of the Board, effective Aug 18, 2025.","COO Christopher Rovaldi to depart Aug 18; Lorena Lerner promoted to CSO; SVP roles eliminated."],"urls":{"canonical":"https://secwatch.observer/filing/0001664710-25-000071","json":"https://secwatch.observer/filing/0001664710-25-000071.json","markdown":"https://secwatch.observer/filing/0001664710-25-000071.md","text":"https://secwatch.observer/filing/0001664710-25-000071.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1664710/000166471025000071/0001664710-25-000071-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1664710/000166471025000071/kros-20250806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:35:56.462374+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}